Findings

What do systematic reviews say?

95 questions · 96 findings · 37 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 24 · 25%GRADE not reported 1 · 1%Very low 30 · 31.3%Low 21 · 21.9%Moderate 12 · 12.5%High 8 · 8.3%

Intervention not reported

Corticosteroids · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Corticosteroids · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Corticosteroids · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.03% vs corticosteroids

Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis

It is very uncertain whether tacrolimus 0.03% changes physician's assessment of global response of improvement, clear or… compared with corticosteroids (very low certainty).

1 finding from 1 review

Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
RR 0.45 [0.13, 1.57]
2 studies · 409 participants
Very low

Stopping LABA vs continuing use of LABA+ICS

Rate of exacerbations requiring systemic corticosteroids · adults with asthma well controlled on LABA and ICS

Stopping LABA showed no clear difference in exacerbation: systemic corticosteroids 17 weeks compared with continuing use of LABA+ICS (moderate certainty).

1 finding from 1 review

Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
OR 1.74 [0.83, 3.65]
4 studies · 1257 participants
Moderate

LAMA add‐on vs ICS alone

Exacerbations (OCS) · adults with asthma not well controlled on ICS

LAMA add‐on leads to lower exacerbations requiring oral corticosteroids (OCS) compared with ICS alone (high certainty).

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for… 2015 · Cochrane Headline outcomes only
OR 0.65 [0.46, 0.93]
4 studies · 2277 participants
High

Intervention not reported

Exacerbations requiring oral corticosteroids 48 weeks · adults with asthma

The intervention showed no clear difference in exacerbations requiring oral corticosteroids 48 weeks (moderate certainty).

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta₂‐agonists and inhaled corticosteroids… 2016 · Cochrane Headline outcomes only
OR 0.76 [0.57, 1.02]
2 studies · 907 participants
Moderate

Intervention not reported

Glucocorticosteroids · adults undergoing liver transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Induction immunosuppression in adults undergoing liver transplantation: a network meta‐analysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐leukotrienes & ICS vs same‐dose ICS

Number of participants experiencing one or more episode requiring treatment with oral steroids · children with asthma

Anti‐leukotrienes & ICS may leads to lower participants with one or more exacerbations requiring oral… compared with same dose ICS (low certainty).

1 finding from 1 review

Addition of anti‐leukotriene agents to inhaled corticosteroids in children with persistent asthma 2013 · Cochrane Headline outcomes only
Risk Ratio 0.8
1 study · 279 participants
Low

Anti‐leukotrienes & ICS vs ICS dose increase

Number of participants experiencing one or more episode requiring treatment with oral steroids · children with asthma

Anti‐leukotrienes & ICS may leads to lower participants with one or more exacerbations requiring oral… compared with higher dose ICS (low certainty).

1 finding from 1 review

Addition of anti‐leukotriene agents to inhaled corticosteroids in children with persistent asthma 2013 · Cochrane Headline outcomes only
Risk Ratio 0.82
1 study · 182 participants
Low

LABA/ICS vs LTRA + ICS

Number of participants with exacerbations requiring systemic steroids · patients with chronic asthma

LABA + ICS leads to lower participants with one or more exacerbations requiring systemic… compared with LTRA + ICS (high certainty).

1 finding from 1 review

Addition to inhaled corticosteroids of long‐acting beta₂‐agonists versus anti‐leukotrienes for chronic asthma 2014 · Cochrane Headline outcomes only
RR 0.87 [0.76, 0.99]
8 studies · 6257 participants
High

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both · patients with chronic obstructive pulmonary disease

It is very uncertain whether once‐daily ICS/LABA combined inhalers changes any COPD exacerbation that requires short‐burst oral corticosteroids… compared with once‐daily LAMA (very low certainty).

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
OR 0.72 [0.35, 1.5]
2 studies · 880 participants
Very low

Intermittent 'as needed' ICS vs daily ICS

Number of participants experiencing one or more episode requiring treatment with oral steroids · Children and adults with persistent asthma.

Intermittent 'as needed' ICS showed no clear difference in patients with 1 or more exacerbations requiring oral corticosteroids… compared with daily ICS (low certainty).

1 finding from 1 review

Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults 2013 · Cochrane Headline outcomes only
RR 1.07 [0.87, 1.32]
7 studies · 1204 participants
Low

Intervention not reported

Patients with ≥ 1 exacerbation requiring oral corticosteroids Duration of trials: 8 to 13 weeks · adults and adolescents with persistent asthma

The intervention showed no clear difference in patients with ≥ 1 exacerbation requiring oral corticosteroids… (moderate certainty).

1 finding from 1 review

Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma 2017 · Cochrane Headline outcomes only
RR 0.9 [0.58, 1.39]
4 studies · 1779 participants
Moderate

Intervention not reported

Patients with ≥ 1 exacerbations requiring oral corticosteroids Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma

The intervention probably leads to lower patients with ≥ 1 exacerbations requiring oral corticosteroids… (moderate certainty).

1 finding from 1 review

Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma 2017 · Cochrane Headline outcomes only
RR 0.5 [0.29, 0.86]
4 studies · 815 participants
Moderate

Intervention not reported

Participants with ≥ 1 exacerbation requiring oral corticosteroids Duration of trials: 8 to 24 weeks · adults and adolescents with persistent asthma

The intervention showed no clear difference in participants with ≥ 1 exacerbation requiring oral corticosteroids… (low certainty).

1 finding from 1 review

Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma 2017 · Cochrane Headline outcomes only
RR 0.46 [0.2, 1.04]
5 studies · 542 participants
Low

Intervention not reported

LASB vs oral corticosteroids · adults with CRPS

1 finding from 1 review

Local anaesthetic sympathetic blockade for complex regional pain syndrome 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Very low

Moisturisers vs no treatment (no moisturiser)

Amount of corticosteroids used · people with eczema

1 finding from 1 review

Emollients and moisturisers for eczema 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 222 participants
Low

Action plan vs usual care

Courses of oral corticosteroids · acute exacerbations of chronic obstructive pulmonary disease

1 finding from 1 review

Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 200 participants
Moderate

Intervention not reported

Tacrolimus plus glucocorticosteroids · people undergoing liver transplantation

1 finding from 1 review

Maintenance immunosuppression for adults undergoing liver transplantation: a network meta‐analysis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low